As the COVID-19 pandemic has developed, concern for invasive fungal infections in critically ill COVID-19 patients with acute respiratory distress syn… "bronchoalveolar lavage or serum is supported by expert groups in Europe pending further research [8]. Experience with empirical or directed use of antifungal agents in the setting of COVID-19 is required, particularly in regards to efficacy, duration of treatment and possible adverse drug reactions in the setting of hepatotoxicity (a not uncommon feature of severe COVID-19), renal compromise, renal dialysis, arrhythmias, and electrolyte imbalance. Drug interactions with concurrent critical care agents or new or proposed COVID-19 specific therapies may influence the choice of an antifungal agent."